Equity Overview
Price & Market Data
Price: $2.20
Daily Change: $0.00 / 0.00%
Daily Range: $2.03 - $2.44
Market Cap: $332,263,712
Daily Volume: 2,820,635
Performance Metrics
1 Week: -10.57%
1 Month: 30.95%
3 Months: 34.97%
6 Months: 60.58%
1 Year: 547.1%
YTD: 34.97%
Company Details
Employees: 23
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.